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Abstract
Purpose: The purpose of this article is to assemble, review, and provide a synopsis of the historical
and current literature regarding optimal sequencing of radiation (RT) and immunotherapy
combination treatments.
Materials and methods: A review of the literature was performed using PubMed with the query
“radiation” and “Immunotherapy”, “PD1”, “PDL1”, “CTLA4”, “OX40”, “checkpoint”, “vaccine”,
“macrophage”, “STING”, and “TGFbeta”. Studies that included sequencing of therapy were
evaluated and the studies were included at the authors discretion.
Results: A paucity of primary literature exists examining the best order of radiation and
immunotherapy, most of which was performed in the pre-clinical setting. The observations are that
optimal sequencing of various radiation plus immune therapy combinations is dependent on the
mechanism(s) of activation by the combination treatment. Immunosuppressive molecules tend to
be better inhibited prior to RT while engagement of costimulatory genes is better activated
concomitantly with RT.
Conclusions: These data should compel more basic research into both the direct investigation of
sequencing efficacy and studies on the mechanisms of immune mediated cell death potentiated by
radio-therapy.
 2018 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Purpose
The advent of immune therapies approved by the U.S.
Food and Drug Administration for patients with late-stage
cancer, which consist primarily of monoclonal antibodies
(mAbs) that neutralize the inhibitory actions of T-cell
checkpoint molecules, has stimulated a wave of research
into novel immune-oncology (IO) combination treatment
strategies. The central hypothesis of these strategies
hinges on the idea that cell-mediated cytotoxicity can be
harnessed and exploited to eradicate existing tumors as
well as surveil undetectable malignancies. The evidence
that necessitates this research is clear, but despite
remarkable responses in melanoma,1 responses to
treatment are much more modest in other tumor types
where the majority of patients do not respond. Among
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patients who exhibit an objective response, many become
therapeutic resistant while on immune checkpoint
blockade (ICB) treatment. As more immunotherapeutic
options become available, determining when to use them
and how to combine them with standard-of-care cytotoxic
therapy is critical.
Radiation is a common antineoplastic treatment
modality that is primarily related to its efficacy as a focal
cytotoxic agent. Additional benefits of radiation are its
ability to expose tumor antigens, create a focal
inflammatory response, enhance major histocompatibility
complex upregulation, induce maturation of antigen-
presenting cells, lead to danger-associated molecule
pattern (DAMP)/pathogen-associated molecular pattern
expression, and sensitize tumor cells to immune-mediated
killing to create a potent in situ vaccine.2e4 Primarily
because of this, combination radiation and immunotherapy
can enhance efficacy over either modality alone. Herein,
we will discuss the data for the most effective combination
of radiation and various immunotherapies to potentiate the
vaccination effect (Table 1). Specifically, we will focus on
the sequencing of treatments to maximize tumor killing
both locally and in metastatic tissues.
Methods and Materials
A review of the literature was performed using PubMed
with the query “radiation” and “Immunotherapy”, “PD1”,
“PDL1”, “CTLA4”, “OX40”, “checkpoint”, “vaccine”,
“macrophage”, “STING”, and “TGFbeta”. Studies that
included sequencing of therapy were evaluated and the
studies were included at the authors discretion.
Results
Combination radiation and immunotherapy
rationale
Although initially approved for metastatic melanoma
with objective response rates up to 40%, some cancers
such as pancreatic adenocarcinoma are virtually
unresponsive to ICB monotherapy.1,5,6 A recently
identified biomarker to predict which patients are
susceptible to ICB efficacy is the categorization of tumors
as those with an already established T-cell inflamed
phenotype (ie, hot tumors) and those with a relative
paucity of T-cell infiltrates (ie, cold tumors) before ICB
treatment.7,8 The influence of T-cell infiltrate on response
to standard-of-care treatment (excluding immunotherapy)
is the number 1 independent prognosticator of
cancer-specific survival in colorectal cancer9,10 and has
led to a 6-year global effort to standardize the
immunoscore as defined by the level of cluster of
differentiation (CD)3þ/8þ T-cell infiltration.
These biomarkers are strongly considered to enhance
patient stratification and likely will be employed for the
clinical practice of some cancer types, which is a
remarkable example of progress and translation from
research to clinical practice. Additional biomarkers for
response to ICB include the sum total of somatic
mutations acquired in an individual’s tumor, which
portends an enhanced immunogenic state because of the
acquisition of neo-antigens presented by cancer cells that
can stimulate endogenous immunity.7,11 Indeed, a strong
association between ICB-responsive patients with higher
tumor mutational burdens has been demonstrated.12
Curiously, these molecular patterns do not explain the
difference between T-cell rich and poor tumors that are
naturally generated from treatment-naïve melanomas.13 To
convert the phenotype of cold tumors into T-cell rich
microenvironments, conventional cytotoxic therapies using
ionizing radiation have significant utility. Radiation
increases tumor-infiltrating T cells, both naïve and
antigen-specific CD8þ T cells.14 Exceedingly rare case
report observations have long ago shown that radiation of
a particular malignant lesion can lead to partial or complete
regression of an unirradiated lesion within the same patient
(abscopal effect).15 This indicates that radiation therapy
(RT) can elicit local and systemic antitumor immunity and
provides an interventional opportunity to increase the
frequency and magnitude of this abscopal response for
complete tumor rejection and immune memory.
Preclinical evidence has revealed that the mechanism
that mediates these abscopal responses is dependent on
CD8þ cytotoxic T lymphocytes. However, differences in
radiation dose, fractionation, and sequence can have
significant alterations on leukocyte function,16,17 which
highlights the need to understand immune response
mechanisms to RT-induced cell death and tissue stress
responses.
Immune-system activation is carefully controlled
within tissues and finely balanced between eliminating
pathogenic insults and repairing damaged tissue while
limiting collateral tissue destruction through the
suppressive actions of various immune regulatory cell
types (eg, Tregs, Bregs, and M2 macrophages, which are
discussed in more detail elsewhere in this issue).18,19
Progressing cancers escape immune recognition and
rejection in large part by co-opting these immune
regulatory cells and wound-repair phenotypes to assist
with angiogenesis, matrix remodeling, and cytotoxic
T-cell inhibition.20 Ionizing radiation can elicit greater
proportions of nearly all these immunoregulatory cell
types attributed to the activation of apoptotic cell death
pathways in these regulatory cells, which favors
resolution of immune function over potentiating
inflammation.19 To capitalize on the window of
immune stimulation after radiation, cell-death-associated
immunosuppression must be counteracted to prolong
T-cell activation and residency within tumors. To that
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Table 1 Reference categorization.
Reference # Reference Preclinical Clinical
Retrospective
Clinical
Prospective
1 Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced
melanoma. N. Engl. J. Med. 369, 122e33 (2013).
x
2 Zhang, B. et al. Induced sensitization of tumor stroma leads to
eradication of established cancer by T cells. J. Exp. Med. 204,
49e55 (2007).
x
3 Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the
peptide repertoire, enhances MHC class I expression, and
induces successful antitumor immunotherapy. J Exp Med.
2006;203(5):1259-1271. https://doi.org/10.1084/jem.20052494
x
4 Ganss, R., Ryschich, E., Klar, E., Arnold, B. & Hämmerling, G. J.
Combination of T-cell therapy and trigger of inflammation
induces remodeling of the vasculature and tumor eradication.
Cancer Res. 62, 1462e70 (2002).
x
5 Brahmer, J. R. et al. Safety and Activity of AntiePD-L1 Antibody
in Patients with Advanced Cancer. N. Engl. J. Med. 366, 2455
e2465 (2012).
x
6 Royal, R. E. et al. Phase 2 trial of single agent Ipilimumab (anti-
CTLA-4) for locally advanced or metastatic pancreatic
adenocarcinoma. J. Immunother. 33, 828e33 (2010).
x
7 Schumacher TN, Schreiber RD. Neoantigens in cancer
immunotherapy. Science. 2015;348(6230):69-74. https://doi.
org/10.1126/science.aaa4971
x
8 Hellmann, M. D. et al. Nivolumab plus Ipilimumab in Lung
Cancer with a High Tumor Mutational Burden. N. Engl. J. Med.
NEJMoa1801946 (2018). https://doi.org/10.1056/NEJMoa1801
946
x
9 Pagès, F. et al. International validation of the consensus
Immunoscore for the classification of colon cancer: a prognostic
and accuracy study. Lancet 1e12 (2018). https://doi.org/10.1
016/S0140-6736(18)30789-X
x
10 Galon, J. et al. Type, density, and location of immune cells within
human colorectal tumors predict clinical outcome. Science 313,
1960e4 (2006).
x
11 Llosa, N. J. et al. The vigorous immune microenvironment of
microsatellite instable colon cancer is balanced by multiple
counter-inhibitory checkpoints. Cancer Discov. 5, 43e51
(2015).
x
12 Snyder, A. et al. Genetic Basis for Clinical Response to CTLA-4
Blockade in Melanoma. Nejm 371, 2189e2199 (2014).
x
13 Spranger, S. et al. Density of immunogenic antigens does not
explain the presence or absence of the T-cell-inflamed tumor
microenvironment in melanoma. Proc. Natl. Acad. Sci. U. S. A.
113, E7759eE7768 (2016).
x
14 Lugade, A. A. et al. Local radiation therapy of B16 melanoma
tumors increases the generation of tumor antigen-specific
effector cells that traffic to the tumor. J. Immunol. 174, 7516e23
(2005).
x
15 Kaur, P. & Asea, A. Radiation-induced effects and the immune
system in cancer. Front. Oncol. 2, 191 (2012).
x
16 Crittenden, M. R. et al. The peripheral myeloid expansion driven
by murine cancer progression is reversed by radiation therapy of
the tumor. PLoS One 8, e69527 (2013).
x
17 Shiao, S. L. et al. TH2-Polarized CD4(+) T Cells and Macrophages
Limit Efficacy of Radiotherapy. Cancer Immunol. Res. 3, 518
e25 (2015).
x
(continued on next page)
496 A.J. Gunderson and K.H. Young Advances in Radiation Oncology: OctobereDecember 2018
Table 1 (continued )
Reference # Reference Preclinical Clinical
Retrospective
Clinical
Prospective
18 Bergsbaken, T., Fink, S. L. & Cookson, B. T. Pyroptosis: host cell
death and inflammation. Nat. Rev. Microbiol. 7, 99e109 (2009).
x
19 Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic
cell death in cancer therapy. Annu. Rev. Immunol. 31, 51e72
(2013).
x
20 Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing
tumor- promoting chronic inflammation: a magic bullet? Science
339, 286e91 (2013).
x
21 Cannarile, M. A. et al. Colony-stimulating factor 1 receptor
(CSF1R) inhibitors in cancer therapy. 1e13 (2017). https://doi.
org/10.1186/s40425-017-0257-y
x
22 Leao, I. C., Ganesan, P., Armstrong, T. D. & Jaffee, E. M.
Effective depletion of regulatory T cells allows the recruitment
of mesothelin-specific CD8+T cells to the antitumor immune
response against a mesothelin-expressing mouse pancreatic
adenocarcinoma. Clin. Transl. Sci. 1, 228e239 (2008).
x
23 Muroyama, Y. et al. Stereotactic Radiotherapy Increases
Functionally Suppressive Regulatory T Cells in the Tumor
Microenvironment. Cancer Immunol. Res. 5, 992e1004 (2017).
x
24 Kaneda, M. M. et al. PI3Kg is a molecular switch that controls
immune suppression. Nature 539, 437e442 (2016).
x
25 Soliman, H. H. et al. A first in man phase I trial of the oral
immunomodulator, indoximod, combined with docetaxel in
patients with metastatic solid tumors. Oncotarget 5, 8136e46
(2014).
x
26 Monjazeb, A. M. et al. Blocking Indolamine-2,3-Dioxygenase
Rebound Immune Suppression Boosts Antitumor Effects of
Radio-Immunotherapy in Murine Models and Spontaneous
Canine Malignancies. Clin. Cancer Res. 22, 4328e40 (2016).
x
27 Morris, Z. S. et al. Tumor-Specific Inhibition of In Situ
Vaccination by Distant Untreated Tumor Sites. Cancer Immunol.
Res. 825e835 (2018). https://doi.org/10.1158/2326-6066.
CIR-17-0353
x
28 Lee, Y. et al. Therapeutic effects of ablative radiation on local
tumor require CD8+ T cells: changing strategies for cancer
treatment. Blood 114, 589e95 (2009).
x
29 Tran, E. et al. T-Cell Transfer Therapy Targeting Mutant KRAS in
Cancer. N. Engl. J. Med. 375, 2255e2262 (2016).
x
30 Tran E, Turcotte S, Gros A, et al. Cancer Immunotherapy Based
on. Science. 2014;9(May):641-645. https://doi.org/10.1126/
science.1251102
x
31 Ott, P. A. et al. An immunogenic personal neoantigen vaccine for
patients with melanoma. Nature 170, 1120e1125.e17 (2017).
x
32 Chamoto, K. et al. Combination immunotherapy with radiation and
CpG-based tumor vaccination for the eradication of radio- and
immuno-resistant lung carcinoma cells. Cancer Sci. 100, 934e9
(2009).
x
33 Hodge, J. W., Sharp, H. J. & Gameiro, S. R. Abscopal regression
of antigen disparate tumors by antigen cascade after systemic
tumor vaccination in combination with local tumor radiation.
Cancer Biother. Radiopharm. 27, 12e22 (2012).
x
34 Crittenden, M. R. et al. Tumor cure by radiation therapy and
checkpoint inhibitors depends on pre-existing immunity. Sci.
Rep. 8, 7012 (2018).
x
35 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next
generation. Cell 144, 646e674 (2011).
x
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36 Dovedi, S. J. et al. Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74, 5458e68 (2014).
x
37 Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy
through inactivation of antigen presentation. Nat. Commun. 8,
1136 (2017).
x
38 Morisada, M. et al. PD-1 blockade reverses adaptive immune
resistance induced by high-dose hypofractionated but not low-
dose daily fractionated radiation. Oncoimmunology 7, e1395996
(2018).
x
39 Antonia, S. J. et al. Durvalumab after Chemoradiotherapy in Stage
III NoneSmall-Cell Lung Cancer. N. Engl. J. Med.
NEJMoa1709937 (2017). https://doi.org/10.1056/NEJMoa17
09937
x
40 Young, K. H. et al. Optimizing Timing of Immunotherapy
Improves Control of Tumors by Hypofractionated Radiation
Therapy. PLoS One 11, e0157164 (2016).
x
41 Gough, M. J. et al. OX40 agonist therapy enhances CD8
infiltration and decreases immune suppression in the tumor.
Cancer Res. 68, 5206e15 (2008).
x
42 Moran, A. E., Kovacsovics-Bankowski, M. & Weinberg, A. D.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer
immunotherapy. Curr. Opin. Immunol. 25, 230e237 (2013).
x
43 Arce Vargas, F. et al. Fc Effector Function Contributes to the
Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell 33,
649e663.e4 (2018).
x x
44 Postow, M. A. et al. Immunologic correlates of the abscopal effect
in a patient with melanoma. N. Engl. J. Med. 366, 925e31
(2012).
x
45 Hiniker, S. M. et al. Translational Oncology A Systemic Complete
Response of Metastatic Melanoma to Local Radiation and
Immunotherapy. 5, 404e407 (2012).
x
46 Twyman-Saint Victor, C. et al. Radiation and dual checkpoint
blockade activate non-redundant immune mechanisms in cancer.
Nature 520, 373e7 (2015).
x x
47 Hiniker, S. M. et al. A Prospective Clinical Trial Combining
Radiation Therapy With Systemic Immunotherapy in Metastatic
Melanoma. Int. J. Radiat. Oncol. Biol. Phys. 96, 578e588
(2016).
x
48 Demaria, S. et al. Immune-mediated inhibition of metastases after
treatment with local radiation and CTLA-4 blockade in a mouse
model of breast cancer. Clin. Cancer Res. 11, 728e34 (2005).
x
49 Baird, J. R. et al. Radiotherapy combined with novel STING-
targeting oligonucleotides results in regression of established
tumors. Cancer Res. 76, 50e61 (2016).
x
50 Deng, L. et al. STING-dependent cytosolic DNA sensing promotes
radiation-induced type I interferon-dependent antitumor
immunity in immunogenic tumors. Immunity 41, 543e852
(2014).
x
51 Woo, S. R. et al. STING-dependent cytosolic DNA sensing
mediates innate immune recognition of immunogenic tumors.
Immunity 41, 830e842 (2014).
x
52 Corrales, L. et al. Direct Activation of STING in the Tumor
Microenvironment Leads to Potent and Systemic Tumor
Regression and Immunity. Cell Rep. 11, (2015).
x
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53 Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates
radiotherapy-induced tumour immunogenicity. Nat. Commun. 8,
15618 (2017).
x
54 Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy
induces an immune-mediated abscopal effect when combined
with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379e88
(2009).
x
55 Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-
Residing Batf3 Dendritic Cells Are Required for Effector T Cell
Trafficking and Adoptive T Cell Therapy. Cancer Cell 31, 711
e723.e4 (2017).
x
56 Noy, R. & Pollard, J. W. Tumor-Associated Macrophages: From
Mechanisms to Therapy. Immunity 41, 49e61 (2014).
x
57 Xu, M. M. et al. Dendritic Cells but Not Macrophages Sense
Tumor Mitochondrial DNA for Cross-priming through Signal
Regulatory Protein a Signaling. Immunity 47, (2017).
x
58 Zhang, J. G. et al. The Dendritic Cell Receptor Clec9A Binds
Damaged Cells via Exposed Actin Filaments. Immunity 36, 646
e657 (2012).
x
59 Hashimoto, D., Miller, J. & Merad, M. Dendritic Cell and
Macrophage Heterogeneity In Vivo. Immunity 35, 323e335
(2011).
x
60 Young, K. H. et al. TGFb Inhibition Prior to Hypofractionated
Radiation Enhances Efficacy in Preclinical Models. Cancer
Immunol. Res. (2014). https://doi.org/10.1158/2326-6066.
CIR-13-0207
x
61 Vanpouille-Box, C. et al. TGFb is a master regulator of radiation
therapy-induced antitumor immunity. Cancer Res. 75, 2232
e2242 (2015).
x
62 Formenti, S. C. et al. Focal Irradiation and Systemic TGFb
Blockade in Metastatic Breast Cancer. Clin. Cancer Res. (2018).
https://doi.org/10.1158/1078-0432.CCR-17-3322
x
63 Bouquet, F. et al. TGFb1 inhibition increases the radiosensitivity
of breast cancer cells in vitro and promotes tumor control by
radiation in vivo. Clin. Cancer Res. 17, 6754e6765 (2011).
x
64 Lan, Y. et al. Enhanced preclinical antitumor activity of M7824, a
bifunctional fusion protein simultaneously targeting PD-L1 and
TGF-b. Sci. Transl. Med. 10, eaan5488 (2018).
x
65 Strauss, J. et al. Phase I Trial of M7824 (MSB0011359C), a
Bifunctional Fusion Protein Targeting PD-L1 and TGFb, in
Advanced Solid Tumors. Clin. Cancer Res. 24, 1287e1295
(2018).
x
66 DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer
survival and functionally regulates response to chemotherapy.
Cancer Discov. 1, 54e67 (2011).
x x
67 Crocenzi, T. et al. A hypofractionated radiation regimen avoids the
lymphopenia associated with neoadjuvant chemoradiation
therapy of borderline resectable and locally advanced pancreatic
adenocarcinoma. J. Immunother. Cancer 4, 1e13 (2016).
x
68 Mosely, S. I. S. et al. Rational Selection of Syngeneic Preclinical
Tumor Models for Immunotherapeutic Drug Discovery. Cancer
Immunol. Res. 5, 29e41 (2017).
x
69 Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium
promotes antitumor immunity and facilitates anti-PD-L1
efficacy. Science. 2015;350(6264):1084-1089. https://doi.org/1
0.1126/science.aac4255
x
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end, performing radiation with therapies that target this
suppression is appealing. Currently, macrophage
inhibitors,21 Treg depletion,22,23 PI3Kg antagonism,24
and indoleamine 2, 3-dioxygenase 1 blockade25,26 are
promising immunoregulatory targets explored in clinical
trials in a variety of indications. Preclinical evidence for
enhanced systemic immune responses after radiation and
immunotherapy when Tregs are depleted has laid the
groundwork to move this research forward to the clinic.27
Altering tumor-infiltrating T cells before
radiation
When formulating the correct sequencing of radiation
and immunotherapies, understanding how the pre-existing
immune microenvironment influences responses to RT is
beneficial. Whole exome sequencing is becoming a
standard laboratory practice for many cancer centers,
primarily to identify molecular targets that can be treated
with small molecule inhibitors of dominant oncogenic
pathways. However, this offers an additional opportunity
to characterize the immunological landscape for research
and therapeutic exploitation, including the identification
of tumor antigens and neoantigens, immune infiltrate and
polarization, and cytokine profile. For those with cold
tumors with potentially hidden or cryptic immune epi-
topes, radiation before whole exome sequencingedirected
vaccination might be counterproductive.
Because response to radiation is partially dependent on
CD8þ T cells,28 strategies to increase T-cell infiltrate may
improve radiation efficacy (Fig 1). Targeting tumor-
cellespecific neoantigens in the forms of personalized
vaccine and antigen-specific T-cell transfer can mediate
tumor regression in patients with treatment-resistant
tumors.39e41 Preclinical studies that combine radiation
and tumor-antigen vaccines have resulted in enhanced
responses over either modality alone,42 but genetic and
cellular heterogeneity between patients likely precludes a
one-size-fits-all approach to this particular combination
therapy.
However, the combination of radiation and specific
tumor-antigen vaccines can lead to the regression of
tumors with disparate antigens because of antigen
cascade.37 Furthermore, T-cell priming to tumor antigens
in implantable mouse models has recently been shown
to occur in direct response to tumor cell injection,
precluding the therapeutic generation of de novo
immunity.43 This provides a unique animal model to
study immune-boosting scenarios to custom antigens, but
is clearly an experimental artifact contrary to the 10-year
average of human carcinogenesis.44
Despite these caveats, the majority of patients with
cancer likely have sufficiently primed T cells at the time
of diagnosis, and thus strategies to boost pre-existing
immunity in these patients using local radiation would
likely focus on enhancing cross-presentation and
promoting TH1 type inflammation. Clearly, more direct
research on the mechanisms of radiation as an in situ
vaccine is necessary to clarify these outstanding
questions, as discussed in this special issue.
Radiation and immune checkpoint blockade
A robust T-cell infiltrate may be rendered ineffective
via upregulation of immune checkpoint molecule
expression. The combination of radiation and checkpoint
blockade aims to enhance T-cell infiltrate into the tumor
and prevent T-cell functional suppression. When
evaluating the ideal timing of radiation and anti-
programmed cell death protein 1 (PD-1) therapy,
concurrent treatment was superior to sequential treatment,
which suggests that an upregulation of anti-PD-1/
programmed death-ligand 1 (PD-L1) occurs rapidly
after radiation (Fig 1).31 This timing is consistent
with radiation-increasing interferon that leads to the
upregulation of immune checkpoints.
Table 1 (continued )
Reference # Reference Preclinical Clinical
Retrospective
Clinical
Prospective
70 Druzd, D. et al. Lymphocyte Circadian Clocks Control Lymph
Node Trafficking and Adaptive Immune Responses Article
Lymphocyte Circadian Clocks Control Lymph Node
Trafficking. Immunity 1e13 (2017). https://doi.org/10.1016/j.
immuni.2016.12.011
x
71 Messenheimer, D. J. et al. Timing of PD-1 blockade is critical to
effective combination immunotherapy with anti-OX40. Clin.
Cancer Res. 23, 6165e6177 (2017).
x
72 Crittenden, M. R. et al. Mertk on tumor macrophages is a
therapeutic target to prevent tumor recurrence following
radiation therapy. Oncotarget 7, (2014).
x
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Furthermore, resistance to ICB alone can develop via
downregulation of antigen presentation machinery,45
which hypofractionated radiation may be able to
salvage.46 Recent data also demonstrate that tumor cures
from radiation and immune checkpoint blockade require
pre-existing immunity, and that treatment does not
generate a sufficient de novo immune response.43
Recently, data from the landmark PACIFIC trial for
patients with stage III locally advanced and unresectable
non-small cell lung cancer revealed that the addition of
consolidation durvalumab (anti-PD-L1 mAb) significantly
improved progression-free survival over placebo plus
chemoradiation alone.47 Although not directly assessing
the difference between radiation and immune-therapy
sequencing, there was an important trend of improved
responses for patients who received anti-PD-L1 mAb
closer to the chemoradiation administration. This
potentially indicates that concomitant combination
therapy may be more optimal than significantly delaying
immune checkpoint blockade.
Of even greater importance may be the responses of
PD-L1 low/negative patients and nonsmokers to
durvalumab therapy, which suggests a potential
conversion of immunogenic-poor patients to T-cell rich
environments by standard cytotoxic therapies. Other
clinical trial results in breast cancer that combine
chemotherapy with ICB mirror the treatment kinetics
observed here (NCT02513472, clinicaltrials.gov).
Converse to the ideal timing of anti-PD-1 mAb around
radiation, a preclinical study evaluating the timing of
radiation and checkpoint blockade with anticytotoxic
T-lymphocyte associated protein 4 (CTLA4) determined
that the combination was the most effective when given 7
days preceding a single 20-Gy dose of radiation as
opposed to concurrently or after RT (Fig 1).29
Interestingly, this timing did not confer efficacy when
using an agonist anti-OX40 antibody in the same model
where 1 day after RT was the most effective course of
combination treatment (Fig 1). This likely reflects the
differing mechanisms of anti-CTLA4 versus anti-OX40
on T-cell biology. CTLA4 is known to raise the
threshold for T-cell priming by blocking co-stimulation
and is constitutively expressed after T-cell priming, but
OX40 is transiently upregulated after antigen exposure
and can serve as a powerful co-stimulatory molecule that
is secondary to others, such as CD28.48,49
In addition, CTLA4 expression is the highest on
regulatory T cells (Tregs), but OX40 expression is
higher on other T-cell subsets, which indicates prefer-
ential binding to different cell populations. Furthermore,
certain antibody isotypes are known to enhance
antibody-dependent cell cytotoxicity of target cells and
in this study, Treg depletion by anti-CTLA4 mAb was
hypothesized to be partially responsible for the enhanced
radiation efficacy. This approach has since been
confirmed in independent studies to specifically deplete
tumor Tregs.27,30 Retrospective clinical reports have
found that the delivery of anti-CTLA4 before radiation
correlated with improved survival.50,51 Consistent with
this observation, 2 phase 1 trials have published their
results combing RT with ipilumimab (Ipi) in patients
with metastatic melanoma. The initial trial delivered
stereotactic body RT followed by 4 cycles of Ipi, and the
second trial delivered Ipi first, followed by RT 5 days
later, then continued Ipi for a total of 4 cycles.
Interestingly, stereotactic body RT followed by Ipi
Figure 1 Ideal efficacy of immune therapies around radiation. Studies demonstrate regulatory T-cell depletion or inhibition before
radiation have enhanced efficacy.29,30 Nondepleting anticytotoxic T-lymphocyte associated protein 4 and antiprogrammed cell death
protein 1 therapy are effective when delivered concurrently with radiation.29,31e33 Agonist anti-OX40 antibodies are most effective
within 24 hours of delivering radiation. Transforming growth factor beta inhibition before and concurrently with radiation has
demonstrated increased efficacy.34,35 Macrophage repolarization after radiation improves radio-response.36 Vaccination before and after
radiation can lead to antigen spreading and systemic tumor responses, including tumors with disparate antigens.37 Stimulator of
interferon gene agonists delivered concurrently and after radiation demonstrate improved efficacy.38
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resulted in an 18% partial response as the best
response52 compared with a 50% complete þ partial
response rate in the trial where Ipi preceded radiation,
which also demonstrated a 27% complete response
rate.53
In addition, the results of a recently completed phase 1
trial that attempted to limit the toxicity of Ipi by directly
injecting tumors with TLR9-agonist SD-101 and Ipi
followed by radiation a day later demonstrated only
1 partial response, with a median time to progression of
3 months (NCT02254772, clinicaltrials.gov). These
results suggest less efficacy that is either related to the
route of administration or the timing of radiation after
injection. Of note, in preclinical models, the sequencing
of anti-CTLA4 concurrently or after radiation still
improved survival relative to radiation alone,
presumably through the effects on the checkpoint
blockade of CD8þ T cells.29
Consistent with these findings, anti-CTLA4 and
radiation efficacy with concurrent therapy was dependent
on CD8 T cells and correlated with decreased
metastases.32 Patients who demonstrated a response to RT
and Ipi had higher levels of central memory CD8þ T cells
and enhanced cytokine production by CD8þ T cells
compared with patients who did not respond.53
Radiation and stimulator of interferon gene
agonists
The stimulator of interferon genes (STING) is the
primary mediator of type 1 interferon upregulation upon
radiation treatment and performs this function through the
recognition of cyclic dinucleotides (CDN) that are derived
from cytosolic DNA. Radiation and CDNs have been
combined using concurrent and post-RT dosing of CDN
for enhanced efficacy, analogous to CDNs as an adjuvant
to the radiation vaccine (Fig 1).38 This timing may be due
to the reported dependency on STING and type 1
interferon upregulation signaling for immune stimulation
by radiation.54e56
Recent work evaluated an additional mechanism by
which combination radiation and anti-CTLA4 enhances
immune-mediated tumor clearance via the STING
pathway.57 Interestingly, the results also report that
dose-dependent upregulation of 3 prime repair
exonuclease 1 (Trex1) expression leads to the degradation
of cytosolic DNA and blunting STING activity. Together,
these data suggest that very high dose radiation may be
poorly immunogenic because of Trex1 degradation of
CDNs. A more in-depth discussion of radiation and DNA
sensing can be found in another review in this special
issue. However, Trex1 expression may explain previous
observations that fractionated doses of radiation better
support CTLA4 combinatorial efficacy.33
Radiation and cytokines
Radiation may serve not only as an enhancer of
tumor antigen cross-presentation,58 but also as a driver
of polarized cytokine microenvironments. Stressed and
dying cells are abundant sources of danger signals such
as high mobility group box 1, heat shock proteins,
adenosine 50-triphosphate, reactive oxygen species, and
double stranded DNA.19 Resident phagocytes such as
dendritic cells and macrophages are keen sensors of
these DAMP, primarily to scavenge off of pathogens but
also repair damaged tissue. The default genetic pro-
gramming of phagocytes after the recognition of
DAMPs is to generate inflammation within the corre-
sponding tissue.
However, in response to granulocytic inflammation,
macrophages quickly convert to T-cell immunosuppres-
sion, tissue remodeling, and the promotion of endothelial
and epithelial cell proliferation. Dendritic cells and
macrophages can be skewed to prolong tissue inflamma-
tion, antigen presentation, and epithelial cell cytostasis if
they are compelled toward phenotypes more commonly
found in acutely infected or inflamed tissues. These
observed phenotypic states are marked by high expression
levels of tumor necrosis factor alpha, interferon
alpha/beta, inducible nitric-oxide synthase, antigen
presentation machinery, costimulatory molecules, and the
T-effector cell chemokines CCL5 and CXCL9/10/
11.59e62
Invariably, in the context of RT, these environments
lead to enhanced tumor rejection accompanied by greater
residency of activated T cells and often incite an abscopal
response that is mediated by the immunologic memory of
tumor-associated antigens. However, radiation often leads
to a wound-healing, immunosuppressive, cytokine
environment that is characterized by a robust M2
macrophage infiltrate, transforming growth factor beta
(TGF-b), and adenosine signaling. The optimal window
for intervention targeting these suppressive pathways
might be concurrent or after RT when immunosuppres-
sion arises. In that regard, TGF-b1 is a master regulator of
wound repair and immunosuppression by promoting
fibroblast proliferation, blocking naïve T-cell prolifera-
tion, and inducing Treg and pericyte differentiation.
Two groups have independently verified the rationale
of combining TGF-b1 inhibition with RT in mice and
humans.34,35,63,64 Of note, the therapeutic reagents
differed in both studies from small molecule antagonism
of TGF-bR1 signaling and antibody neutralization of
TGF-b1 cytokine, but both preclinical studies delivered
treatment in the same sequence (TGF-b1 blockade
followed by radiation; Fig 1). Because of increased
interferon expression after TGF-b1 inhibition and
radiation leading to the upregulation of PD-L1, the
addition of checkpoint blockade to this regimen has
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proven effective.35,65,66 Contrarily, macrophage depletion
before chemotherapy and radiation in breast cancer mouse
models uniformly demonstrated enhanced cytotoxic
responses,17,67 which suggests tumor tissue type and
perhaps oncogenic signaling may affect sequencing
decisions.
Fractionated radiation and timing of
immunotherapy
The expansion of our knowledge of these systems,
both on the tissue and molecular levels, is requisite to the
precise timing of immunotherapy administered around
traditional cytotoxic approaches. Most of the evidence
presented herein relates to 1 to 5 doses of radiation, as
opposed to the more common clinical scenario of standard
fractionated radiation over weeks to months. How
fractionated radiation influences the ideal timing of
immunotherapy has been more challenging to address in
preclinical models. One concern with regard to
combination immunotherapy and standard fractionated
radiation is the depletion of T cells in the irradiated field
after RT15 because this is expected to attenuate antitumor
immunity. Targeted RT modalities using image-guided
conformal RT greatly minimize the field size that is
exposed to radiation; thus, blood volume exposure is
reduced (discussed elsewhere in this issue).
Altering the dose-to-delivery equivalent to increased
bio-equivalent doses in fewer fractions with higher daily
doses (hypofractionation) also results in decreased blood
volume exposure and more immunogenic tumor cell
death. Dose and fractionation influence on antitumor
immunity is discussed in depth elsewhere in this special
edition as well. There is limited evidence on how best to
sequence immunotherapy with a standard fractionated
radiation, but analyses of immune parameters provide
important information that will impact IO RT trial designs
so that the timing of immune therapies can be coordinated
within the window of greatest opportunity.
For example, an analysis of peripheral blood samples
from 2 independent, nonrandomized, clinical trials
indicated that 30 Gy over 3 fractions in 1 week attenuated
peripheral lymphopenia compared with standard 50.4 Gy
over 28 daily fractions in patients with borderline
resectable and locally advanced pancreatic ductal adeno-
carcinoma who received neoadjuvant chemoradiation.68
Importantly, both treatment groups qualified for surgery
in comparable proportions on the basis of a radiographic
assessment, but the duration to normalization of absolute
lymphocyte count was significantly lower in the
hypofractionation group, which indicates that bone
marrow and secondary lymphoid organ reserves were
spared from the depletive effects of RT.
These data suggest that fractionated radiation might
not pair well with T-cell targeting therapies such as
vaccines, checkpoint inhibitors, and agonist costimulatory
antibodies. However, macrophage blockade or antigen-
presenting cell adjuvants may have activity and enhance
responses to standard fractionated radiation given their
relative radioresistance compared with lymphocytes. Of
note, T cells are constantly trafficking, and even though
peripheral lymphopenia is observed with fractionated RT,
that may not reflect the T-cell population in the tumor
microenvironment, as evidenced by the recent PACIFIC
trial in which peripheral lymphopenia was almost
certainly present in patients when they initiated durvalu-
mab, and yet T-cell targeted therapy was still efficacious.
Conclusions
We outline the current knowledge in the field of
radiation and IO combinations but admittedly fail to
sufficiently address the gap in knowledge of how to
correctly sequence these combinations. Indeed, precious
few studies have directly compared the efficacy of
ordering pre-, post-, and concurrent radiation treatments
around various IO modalities (Fig 1). The few studies that
have attempted to explore these questions have typically
done so with strongly immunogenic implantable mouse
models or have observed changes in primary tumor
burden, which rarely accounts for cancer-related fatalities.
Conflicting data exist in preclinical models.
Differences between study results must be viewed in the
context in which these studies are executed. Not only will
differing mouse strains dictate unique biology, but so can
tissue type, tumor model,69 vivarium microbiome,70 and
even circadian rhythms,71 analogous to unique patient
responses to immunotherapy.
Further consideration must be given to the over-
stimulation of the immune system with combination
therapy leading to feedback suppression. For example,
one study examined the efficacy of anti-PD-1 checkpoint
blockade pre- and postcostimulation with anti-OX40 in a
middle T-antigen driven luminal B mammary carcinoma
model. Not only did the researchers observe an
enhancement of tumor kill when administering anti-PD-1
antibody after anti-OX40, but also reported a direct
antagonism of efficacy when concurrently giving both
antibodies.72 The most probabilistic explanation is that
when PD-1 signaling is blocked too soon after OX40 co-
stimulation, T-cell exhaustion is accelerated and T-cell
cytotoxicity is rendered less effective. This clearly has
translational relevance to strictly immune-based combi-
nations, but we believe that radiation could mirror the co-
stimulatory effects that are provided by therapeutic
intervention.
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As demonstrated in this review, the mechanism of
immune therapy that is used will directly influence the
ideal timing in combination with radiation. Further studies
are needed to optimize our efforts. We urge the radiation
oncology community to embrace these research efforts to
rationally design clinical trials based on preclinical data
and with consideration for the immunotherapy mecha-
nism of action.
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